Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review
Open Access
- 8 April 2025
- journal article
- Published by Wiley in Health Science Reports
- Vol. 8 (4) , e70626
Abstract
Background and Aims: Breast cancer is the most common cancer and a leading cause of cancer‐related death among women globally. Determining which patients will benefit from chemotherapy remains challenging. Proliferative markers such as Ki‐67, mini chromosome maintenance (MCM) proteins, and proliferating cell nuclear antigen (PCNA) offer valuable insights into tumor growth and treatment response. This review evaluates their clinical roles, with a focus on chemotherapy implications and emerging digital pathology techniques for marker quantification.Methods: A narrative review was conducted by searching PubMed, Scopus, and Google Scholar for studies related to Ki‐67, MCM, PCNA, breast cancer, and chemotherapy. Studies were thematically categorized into five areas. A bibliometric analysis of publications from 2000 to April 2023 was performed using the Bibliometrix R package and VOSviewer to assess research trends and thematic evolution.Results: Eighty studies were included in the narrative synthesis. Ki‐67 is the most commonly used marker, particularly useful in predicting response to neoadjuvant chemotherapy (NAC). MCM proteins show promise for identifying proliferative potential across tumor grades, while PCNA is associated with aggressive tumor features and poor prognosis. Post‐chemotherapy changes in Ki‐67 levels are linked to survival outcomes. Bibliometric analysis revealed a shift in research focus from basic mechanisms to clinical applications and digital quantification.Conclusion: Proliferative markers play an essential role in breast cancer management. Ki‐67 remains a key predictor of chemotherapy response, while MCM and PCNA offer complementary prognostic insights. Integration of these markers with digital pathology and AI‐driven tools may enhance diagnostic accuracy and personalized treatment strategies. Standardization of assessment methods is crucial for broader clinical application.Keywords
This publication has 80 references indexed in Scilit:
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- The MCM Complex: Its Role in DNA Replication and Implications for Cancer TherapyCurrent Cancer Drug Targets, 2005
- Minichromosome Maintenance Protein 2 Is a Strong Independent Prognostic Marker in Breast CancerJournal of Clinical Oncology, 2003
- Early changes in apoptosis and proliferation following primary chemotherapy for breast cancerBritish Journal of Cancer, 2003
- An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancerBreast Cancer, 2002
- Minichromosome maintenance (MCM) proteins may be pre-cancer markersGut, 2002
- Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancerBritish Journal of Cancer, 2001
- Faculty Opinions recommendation of DNA replication licensing and human cell proliferation.2001
- The Ki-67 protein: From the known and the unknownJournal of Cellular Physiology, 2000
- Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some, neoplasmsThe Journal of Pathology, 1990